Novel Anti-Infective Treatments

We are committed to delivering innovative anti-infective therapies for difficult-to-treat and often life-threatening infections. We are developing Ibrexafungerp (formerly SCY-078), the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family, for the treatment of several serious fungal infections, including vulvovaginal candidiasis (VVC), invasive candidiasis, invasive aspergillosis and refractory invasive fungal infections.

A Versatile Anti-InfectiveJoin our Clinical Trials


Click here for our list of Frequently Asked Questions

View FAQs

Driven to Solve Global Health Threats and to Positively Impact the Lives of Patients

Our team strives to save and improve patients' lives. We are committed to developing and delivering innovative therapies to address difficult-to-treat and often life-threatening infections, and to transforming treatment paradigms for patients worldwide.

More About Us

Our Innovative Antifungal Platform

Our lead candidate, Ibrexafungerp (formerly SCY-078), currently in Phase 2 clinical development, is a novel and structurally distinct glucan synthase inhibitor. It is the first representative of a new triterpenoid antifungal family.

Our Science Our Pipeline

Success Backed by Strong Leadership

The innovation that drives our science and pipeline is a direct reflection of our leadership's passion for improving patients' lives. This leadership has a proven track record of drug development and commercialization, and deep antifungal expertise.

Leadership Board of Directors



Nasdaq: SCYX



52-Week Range

Daily Volume

Day Range

Email Alerts

Receive the latest news directly to your inbox

Sign Up